Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...

U.S. drugmaker Pfizer said on Monday it has signed a licensing agreement worth about $6 billion with Chinese biopharmaceutical company 3SBio Inc for the development, manufacturing and ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

The deal grants Pfizer rights to develop and commercialize a drug from Shenyang-based 3SBio Inc. currently in clinical testing for multiple tumor types, according to a press release. In addition ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...